Patents by Inventor Jamshid Tanha
Jamshid Tanha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240156870Abstract: Herein are provided anti-EGFR single domain antibodies (sdAb) prepared by immunizing a llama with recombinant human EGFRvIII. VHH antibodies specific to EGFR were isolated. The example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQ NOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16-18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, and 46-48; and related sequences, including humanized variants. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancer are also described, in particularly EGFR-high cancers. Hinge lengths may be selected to achieve desired activities, such as high activity or high selectivity for target vs. non-target cells.Type: ApplicationFiled: October 28, 2021Publication date: May 16, 2024Inventors: Kevin HENRY, Martin ROSSOTTI, Mehdi ARBABI-GHAHROUDI, Scott MCCOMB, Risini WEERATNA, Jamshid TANHA
-
Patent number: 11384141Abstract: The present document describes an antibody or an antigen-binding fragment that bind to serum albumin comprising three complementarity determining regions (CDR1, CDR2 and CDR3), for half-life extension of biologics. The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of removing molecules from serum.Type: GrantFiled: April 24, 2019Date of Patent: July 12, 2022Assignee: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Gregory Hussack, Jamshid Tanha, Kevin Henry, Traian Sulea
-
Patent number: 11242386Abstract: A chimeric antigen receptor (CAR) that binds to CEACAM6, an epitope or fragment thereof, or a variant thereof.Type: GrantFiled: July 17, 2017Date of Patent: February 8, 2022Inventors: Heman Lap Man Chao, Wah Yau Wong, Baomin Tian, Lakshmi Krishnan, Jamshid Tanha, Marni Diane Uger
-
Publication number: 20220017603Abstract: Polypeptides with biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human heavy and light chain variable domains (VHs and VLs), are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.Type: ApplicationFiled: July 12, 2021Publication date: January 20, 2022Applicant: National Research Council of CanadaInventor: Jamshid TANHA
-
Publication number: 20210253679Abstract: The present document describes an antibody or an antigen-binding fragment that bind to serum albumin comprising three complementarity determining regions (CDR1, CDR2 and CDR3), for half-life extension of biologics. The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of removing molecules from serum.Type: ApplicationFiled: April 24, 2019Publication date: August 19, 2021Inventors: Gregory HUSSACK, Jamshid TANHA, Kevin HENRY, Traian SULEA
-
Patent number: 11091536Abstract: Polypeptides with biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human heavy and light chain variable domains (VHs and VLs), are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHS and VLs may be subjected to DNA shuffling to select for improved biophysical properties.Type: GrantFiled: December 5, 2018Date of Patent: August 17, 2021Assignee: NATIONAL RESEARCH COUNCIL OF CANADAInventor: Jamshid Tanha
-
Publication number: 20210171613Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for TcdA. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.Type: ApplicationFiled: July 9, 2018Publication date: June 10, 2021Applicant: National Research Council of CanadaInventors: Traian SULEA, Gregory HUSSACK, Jamshid TANHA, Enrico O. PURISIMA
-
Patent number: 10633430Abstract: The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a VH, the Cys may be introduced at any one of positions 47-49 and any one of positions 67-71, based on Kabat numbering; in one example, the Cys may be introduced at positions 49 and 69, based on Kabat numbering. In the case where the sdAb scaffold is a VL, the Cys residues may be introduced at any one of positions 46-49 and any one of positions 62-66, based on Kabat numbering; in one example, the Cys residues may be introduced at positions 48 and 64, based on Kabat numbering.Type: GrantFiled: June 10, 2016Date of Patent: April 28, 2020Assignee: National Research Council of CanadaInventors: Dae Young Kim, Jamshid Tanha
-
Patent number: 10259864Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: GrantFiled: December 20, 2017Date of Patent: April 16, 2019Assignee: National Research Council of CanadaInventors: Mehdi Arbabi Ghahroudi, Ali Riazi, Christine M. Szymanski, Greg Hussack, Jamshid Tanha, Roger MacKenzie
-
Publication number: 20190092840Abstract: Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.Type: ApplicationFiled: December 5, 2018Publication date: March 28, 2019Applicant: National Research Council of CanadaInventor: Jamshid Tanha
-
Patent number: 10150807Abstract: Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.Type: GrantFiled: September 11, 2015Date of Patent: December 11, 2018Assignee: National Research Council of CanadaInventor: Jamshid Tanha
-
Publication number: 20180142000Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: ApplicationFiled: December 20, 2017Publication date: May 24, 2018Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Mehdi ARBABI GHAHROUDI, Ali RIAZI, Christine M. SZYMANSKI, Greg HUSSACK, Jamshid TANHA, Roger MACKENZIE
-
Publication number: 20180134769Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.Type: ApplicationFiled: September 22, 2017Publication date: May 17, 2018Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Greg HUSSACK, Mehdi ARBABI-GHAHROUDI, Roger MACKENZIE, Jamshid TANHA
-
Patent number: 9926363Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: GrantFiled: October 24, 2013Date of Patent: March 27, 2018Assignee: National Research Council of CanadaInventors: Mehdi Arbabi Ghahroudi, Ali Riazi, Christine M. Szymanski, Greg Hussack, Jamshid Tanha, Roger MacKenzie
-
Publication number: 20180016337Abstract: A chimeric antigen receptor (CAR) that binds to CEACAM6, an epitope or fragment thereof, or a variant thereof.Type: ApplicationFiled: July 17, 2017Publication date: January 18, 2018Inventors: Heman Lap Man CHAO, Wah Yau WONG, Baomin TIAN, Lakshmi KRISHNAN, Jamshid TANHA, Marni Diane UGER
-
Patent number: 9771416Abstract: The present invention is directed to Clostridium difficile toxin-specific antibodies, compositions, and uses thereof. The anti-toxin antibodies may be specific for either TcdA or TcdB. The invention also includes methods of treating a Clostridium difficile infection, methods of capturing Clostridium difficile toxins, and methods of detecting Clostridium difficile toxins.Type: GrantFiled: October 25, 2011Date of Patent: September 26, 2017Assignee: National Research Council of CanadaInventors: Greg Hussack, Mehdi Nath Arbabi-Ghahroudi, Roger Mackenzie, Jamshid Tanha
-
Publication number: 20170044238Abstract: The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a VH, the Cys may be introduced at any one of positions 47-49 and any one of positions 67-71, based on Kabat numbering; in one example, the Cys may be introduced at positions 49 and 69, based on Kabat numbering. In the case where the sdAb scaffold is a VL, the Cys residues may be introduced at any one of positions 46-49 and any one of positions 62-66, based on Kabat numbering; in one example, the Cys residues may be introduced at positions 48 and 64, based on Kabat numbering.Type: ApplicationFiled: June 10, 2016Publication date: February 16, 2017Applicant: National Research Council of CanadaInventors: Dae Young Kim, Jamshid Tanha
-
Patent number: 9371371Abstract: The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a VH, the Cys may be introduced at any one of positions (47-49) and any one of positions (67-71), based on Kabat numbering; in one example, the Cys may be introduced at positions (49) and (69), based on Kabat numbering. In the case where the sdAb scaffold is a VL, the Cys residues may be introduced at any one of positions 46-49 and any one of positions (62-66), based on Kabat numbering; in one example, the Cys residues may be introduced at positions (48 and 64), based on Kabat numbering.Type: GrantFiled: January 27, 2012Date of Patent: June 21, 2016Assignee: National Research Council of CanadaInventors: Dae Young Kim, Jamshid Tanha
-
Publication number: 20160052995Abstract: Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties.Type: ApplicationFiled: September 11, 2015Publication date: February 25, 2016Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventor: Jamshid TANHA
-
Publication number: 20150307597Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.Type: ApplicationFiled: October 24, 2013Publication date: October 29, 2015Applicant: NATIONAL RESEARCH COUNCIL OF CANADAInventors: Mehdi ARBABI GHAHROUDI, Ali RIAZI, Christine M. SZYMANSKI, Greg HUSSACK, Jamshid TANHA, Roger MACKENZIE